Compare abrdn Income Credit Strategies Fund (ACP) vs Amylx Pharmaceuticals Inc (AMLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs Amylx Pharmaceuticals Inc — how do they compare? abrdn Income Credit Strategies Fund trades at $5.11 (market cap $637.39M), while Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B). The key difference: Amylx Pharmaceuticals Inc is far larger — about 4× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays a 18.31% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ACP | AMLX | |
|---|---|---|
Market Cap | $637.39M | $2.53B |
Sector | Financials | Health |
52-Week High | $5.98 | $24.19 |
52-Week Low | $5.01 | $7.82 |
Dividend Yield | 18.31% | — |
Enterprise Value | — | $2.28B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.08, up 0.4% today, with a bearish technical signal from moving averages and a neutral stance from oscillators. The stock shows a low P/E of 7.7 and P/B of 0.9, indicating potential undervaluation, while net income margin remains high at 95.31%. Recent news highlights dividend declarations but also concerns over distribution sustainability from Seeking Alpha (2026-05-29).
The outlook is mixed: attractive valuation and dividends offer income appeal, but technical weakness and high distribution reliance pose risks. Investors should weigh the fund's high yield against credit spread tightness and leverage exposure noted in analyst reports.
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →
